HNGZY:OTC-Hangzhou Tigermed Consulting Co. Ltd (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 4.2

Change

0.00 (0.00)%

Market Cap

USD 5.92B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
LZAGF Lonza Group Ltd

N/A

USD 40.41B
LZAGY Lonza Group AG

N/A

USD 40.33B
WUXIF WuXi AppTec Co. Ltd

N/A

USD 16.98B
BMXMF bioMérieux S.A

N/A

USD 12.65B
ERFSF Eurofins Scientific SE

N/A

USD 12.53B
SKHCF Sonic Healthcare Limited

N/A

USD 8.77B
SKHHY Sonic Healthcare Ltd ADR

N/A

USD 8.63B
DSRLF DiaSorin S.p.A

N/A

USD 5.81B
VIMGF Vimian Group AB (publ)

N/A

USD 1.70B
MRCHF H.U. Group Holdings Inc

N/A

USD 0.90B

ETFs Containing HNGZY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -63.48% 29% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.48% 29% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.53% 16% F 19% F
Dividend Return -13.53% 16% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.68% 93% A 78% C+
Risk Adjusted Return -52.67% 15% F 14% F
Market Capitalization 5.92B 89% A- 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector